{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:53:23Z","timestamp":1794362003082,"version":"4.9.0"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270147"],"award-info":[{"award-number":["82270147"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.blre.2025.101273","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T23:33:54Z","timestamp":1740094434000},"page":"101273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies"],"prefix":"10.1016","volume":"71","author":[{"given":"Xin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoren","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aichun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.blre.2025.101273_bb0005","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of Ibrutinib plus rituximab in Waldenstrom\u2019s Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"10020","key":"10.1016\/j.blre.2025.101273_bb0010","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.blre.2025.101273_bb0015","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.blre.2025.101273_bb0020","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2025.101273_bb0025","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2025.101273_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2020.129531","article-title":"Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton\u2019s tyrosine kinase reveals differences in on - and off - target inhibition","volume":"1864","author":"Liclican","year":"2020","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"18","key":"10.1016\/j.blre.2025.101273_bb0035","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1080\/14656566.2022.2144218","article-title":"Evaluating orelabrutinib as a novel treatment option for relapsed\/refractory chronic lymphocytic leukemia in China","volume":"23","author":"Gu","year":"2022","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.blre.2025.101273_bb0040","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","article-title":"Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies","volume":"14","author":"Gu","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.blre.2025.101273_bb0045","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.blre.2025.101273_bb0050","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.cellsig.2010.03.001","article-title":"The Src, Syk, and Tec family kinases: distinct types of molecular switches","volume":"22","author":"Bradshaw","year":"2010","journal-title":"Cell Signal"},{"issue":"2","key":"10.1016\/j.blre.2025.101273_bb0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4049\/jimmunol.152.2.557","article-title":"Expression of Bruton\u2019s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells","volume":"152","author":"Smith","year":"1994","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.blre.2025.101273_bb0060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton\u2019s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.blre.2025.101273_bb0065","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.15108","article-title":"Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects","volume":"181","author":"Hershkovitz-Rokah","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101273_bb0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.blre.2025.101273_bb0075","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.blre.2025.101273_bb0080","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.blre.2025.101273_bb0085","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","article-title":"The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia","volume":"23","author":"Herman","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2025.101273_bb0090","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1097-2765(02)00739-6","article-title":"Amplification of B cell antigen receptor signaling by a Syk\/ITAM positive feedback loop","volume":"10","author":"Rolli","year":"2002","journal-title":"Mol Cell"},{"issue":"5","key":"10.1016\/j.blre.2025.101273_bb0095","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S1074-7613(00)80568-3","article-title":"CD19 as a membrane-anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav","volume":"8","author":"O\u2019Rourke","year":"1998","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.blre.2025.101273_bb0100","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1074-7613(00)00079-0","article-title":"BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation","volume":"13","author":"Okada","year":"2000","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.blre.2025.101273_bb0105","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/13543784.2018.1482273","article-title":"Targeting the B cell receptor pathway in non-Hodgkin lymphoma","volume":"27","author":"Valla","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"43","key":"10.1016\/j.blre.2025.101273_bb0110","doi-asserted-by":"crossref","first-page":"30644","DOI":"10.1074\/jbc.274.43.30644","article-title":"Syk and Bruton\u2019s tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt","volume":"274","author":"Craxton","year":"1999","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.blre.2025.101273_bb0115","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1074-7613(03)00297-8","article-title":"BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity","volume":"19","author":"Saito","year":"2003","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.blre.2025.101273_bb0120","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R","article-title":"Interaction of SLP adaptors with the SH2 domain of Tec family kinases","volume":"29","author":"Su","year":"1999","journal-title":"Eur J Immunol"},{"issue":"434","key":"10.1016\/j.blre.2025.101273_bb0125","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aad6275","article-title":"The adaptor protein CIN85 assembles intracellular signaling clusters for B cell activation","volume":"9","author":"Kuhn","year":"2016","journal-title":"Sci Signal"},{"issue":"Pt 1","key":"10.1016\/j.blre.2025.101273_bb0130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1042\/bst0320113","article-title":"B-cell antigen receptor activates transcription factors NFAT (nuclear factor of activated T-cells) and NF-kappaB (nuclear factor kappaB) via a mechanism that involves diacylglycerol","volume":"32","author":"Antony","year":"2004","journal-title":"Biochem Soc Trans"},{"issue":"7","key":"10.1016\/j.blre.2025.101273_bb0135","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.188.7.1287","article-title":"Involvement of guanosine triphosphatases and phospholipase C-gamma2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor","volume":"188","author":"Hashimoto","year":"1998","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.blre.2025.101273_bb0140","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1084\/jem.20051591","article-title":"PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1","volume":"202","author":"Shinohara","year":"2005","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.blre.2025.101273_bb0145","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000034","article-title":"The NF-kappaB family of transcription factors and its regulation","volume":"1","author":"Oeckinghaus","year":"2009","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"10.1016\/j.blre.2025.101273_bb0150","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.blre.2025.101273_bb0155","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101273_bb0160","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"42","key":"10.1016\/j.blre.2025.101273_bb0165","doi-asserted-by":"crossref","first-page":"68833","DOI":"10.18632\/oncotarget.11932","article-title":"Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL","volume":"7","author":"Sharma","year":"2016","journal-title":"Oncotarget"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2025.101273_bb0170","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2019-127674","article-title":"Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2025.101273_bb0175","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood.2023023659","article-title":"Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101273_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3164_163","article-title":"Characterization of mechanisms of resistance in previously treated chronic lymphocytic leukemia (CLL) from a head-to-head trial of acalabrutinib versus ibrutinib","volume":"41","author":"Woyach","year":"2023","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101273_bb0185","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.18162","article-title":"A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed\/refractory B-cell malignancies","volume":"198","author":"Song","year":"2022","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101273_bb0190","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1182\/blood-2022-170985","article-title":"Novel BTK mutations conferring resistance to the second-generation, irreversible BTK inhibitor orelabrutinib (ICP-022)","volume":"140","author":"Huayuan Zhu","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2025.101273_bb0195","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101273_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3163_116","article-title":"Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor pre-treated chronic lymphocytic leukemia patients: results from the phase I\/II bruin study","volume":"41","author":"Patel","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101273_bb0205","first-page":"rs.3","article-title":"Mutations detected in real world clinical sequencing during BTK inhibitor treatment in CLL","author":"Brown","year":"2024","journal-title":"Res Sq"},{"issue":"6682","key":"10.1016\/j.blre.2025.101273_bb0210","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.blre.2025.101273_bb0215","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2025.101273_bb0220","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2025.101273_bb0225","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2019-127674","article-title":"Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2025.101273_bb0230","first-page":"835","article-title":"Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies","volume":"109","author":"Woolston","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2025.101273_bb0235","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101273_bb0240","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3109\/10428194.2015.1113276","article-title":"CD79B limits response of diffuse large B cell lymphoma to ibrutinib","volume":"57","author":"Kim","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2025.101273_bb0245","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2022-169574","article-title":"Inhibition of MAPK-ERK signaling pathway overcomes microrna-mediated ibrutinib resistance in mantle cell lymphoma","volume":"140","author":"Kersy","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2025.101273_bb0250","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","article-title":"BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib","volume":"7","author":"Bonfiglio","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.blre.2025.101273_bb0255","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/ni.2065","article-title":"Crosstalk in NF-kappaB signaling pathways","volume":"12","author":"Oeckinghaus","year":"2011","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.blre.2025.101273_bb0260","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1084\/jem.20142009","article-title":"Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia","volume":"212","author":"Mansouri","year":"2015","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.blre.2025.101273_bb0265","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/ni.1678","article-title":"Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling","volume":"9","author":"Vallabhapurapu","year":"2008","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.blre.2025.101273_bb0270","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3324\/haematol.2019.219550","article-title":"Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia","volume":"105","author":"Diop","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.blre.2025.101273_bb0275","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.31831","article-title":"Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation","volume":"125","author":"Kanagal-Shamanna","year":"2019","journal-title":"Cancer"},{"issue":"5870","key":"10.1016\/j.blre.2025.101273_bb0280","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.blre.2025.101273_bb0285","series-title":"Experimental and Molecular Therapeutics","article-title":"Abstract 1742: Ibrutinib plus proteasome or MALT1 inhibitors overcome resistance to BCR antagonists in CARD11 mutant-expressing B-lymphoma cells","author":"Xue","year":"2015"},{"key":"10.1016\/j.blre.2025.101273_bb0290","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.blre.2025.101273_bb0295","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/QAD.0b013e32831cb907","article-title":"HAART reduces death ligand but not death receptors in lymphoid tissue of HIV-infected patients and simian immunodeficiency virus-infected macaques","volume":"23","author":"Herbeuval","year":"2009","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.blre.2025.101273_bb0300","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2015.316","article-title":"BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia","volume":"30","author":"Chen","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2025.101273_bb0305","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41375-024-02301-y","article-title":"Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia","volume":"38","author":"Pozzo","year":"2024","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2025.101273_bb0310","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/leu.2014.122","article-title":"Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study","volume":"28","author":"Herman","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2025.101273_bb0315","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.blre.2025.101273_bb0320","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood-2012-04-423517","article-title":"High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations","volume":"120","author":"Edelmann","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2025.101273_bb0325","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/leu.2017.100","article-title":"Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1","volume":"31","author":"Cosson","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.blre.2025.101273_bb0330","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41571-024-00956-1","article-title":"Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia","volume":"21","author":"Stanchina","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101273_bb0335","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101273_bb0340","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.trecan.2019.05.001","article-title":"Targeting the tumor microenvironment of leukemia and lymphoma","volume":"5","author":"Hopken","year":"2019","journal-title":"Trends Cancer"},{"issue":"10","key":"10.1016\/j.blre.2025.101273_bb0345","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLCgamma2","volume":"198","author":"Spaargaren","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2025.101273_bb0350","first-page":"14","volume":"11","author":"Polcik","year":"2022","journal-title":"Integrin Signaling Shaping BTK-Inhibitor Resistance Cells"},{"issue":"2","key":"10.1016\/j.blre.2025.101273_bb0355","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.20171288","article-title":"Functional and clinical relevance of VLA-4 (CD49d\/CD29) in ibrutinib-treated chronic lymphocytic leukemia","volume":"215","author":"Tissino","year":"2018","journal-title":"J Exp Med"},{"issue":"18","key":"10.1016\/j.blre.2025.101273_bb0360","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1158\/1078-0432.CCR-22-3217","article-title":"CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy","volume":"29","author":"Alsadhan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"11\u221212","key":"10.1016\/j.blre.2025.101273_bb0365","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2119\/molmed.2011.00360","article-title":"Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born\/divided and older\/quiescent cells","volume":"17","author":"Calissano","year":"2011","journal-title":"Mol Med"},{"issue":"21","key":"10.1016\/j.blre.2025.101273_bb0370","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","article-title":"Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL","volume":"123","author":"Herman","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2025.101273_bb0375","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2141.2011.08951.x","article-title":"The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival","volume":"156","author":"Obrador-Hevia","year":"2012","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2025.101273_bb0380","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41419-019-2158-0","article-title":"Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies","volume":"10","author":"Kapoor","year":"2019","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.blre.2025.101273_bb0385","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1 - from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2025.101273_bb0390","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3109\/10428194.2015.1106533","article-title":"Metabolism pathways in chronic lymphocytic leukemia","volume":"57","author":"Rozovski","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.blre.2025.101273_bb0395","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40164-022-00292-z","article-title":"Targeting metabolic reprogramming in chronic lymphocytic leukemia","volume":"11","author":"Nie","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101273_bb0400","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3389\/fonc.2018.00411","article-title":"Ibrutinib resistance is reduced by an inhibitor of fatty acid oxidation in primary CLL lymphocytes","volume":"8","author":"Galicia-Vazquez","year":"2018","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.blre.2025.101273_bb0405","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.blre.2025.101273_bb0410","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.blre.2025.101273_bb0415","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1182\/bloodadvances.2022008955","article-title":"Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors","volume":"7","author":"Qi","year":"2023","journal-title":"Blood Adv"},{"issue":"25","key":"10.1016\/j.blre.2025.101273_bb0420","doi-asserted-by":"crossref","first-page":"38180","DOI":"10.18632\/oncotarget.9500","article-title":"Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"issue":"45","key":"10.1016\/j.blre.2025.101273_bb0425","doi-asserted-by":"crossref","first-page":"73558","DOI":"10.18632\/oncotarget.12434","article-title":"CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma","volume":"7","author":"Mohanty","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.blre.2025.101273_bb0430","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.12974","article-title":"Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells","volume":"166","author":"Ma","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101273_bb0435","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.blre.2025.101273_bb0440","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/1535-7163.MCT-17-0784","article-title":"p110alpha inhibition overcomes stromal cell-mediated ibrutinib resistance in mantle cell lymphoma","volume":"17","author":"Guan","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.blre.2025.101273_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000013","article-title":"Sensing and integration of Erk and PI3K signals by Myc","volume":"4","author":"Lee","year":"2008","journal-title":"PLoS Comput Biol"},{"issue":"32","key":"10.1016\/j.blre.2025.101273_bb0450","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1038\/onc.2017.95","article-title":"Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition","volume":"36","author":"Moyo","year":"2017","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.blre.2025.101273_bb0455","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/bloodadvances.2018016048","article-title":"Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma","volume":"2","author":"Lee","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2025.101273_bb0460","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/ja.2011.60","article-title":"Molecular basis for the actions of Hsp90 inhibitors and cancer therapy","volume":"64","author":"Yamaki","year":"2011","journal-title":"J Antibiot (Tokyo)"},{"issue":"6","key":"10.1016\/j.blre.2025.101273_bb0465","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","article-title":"The onco-embryonic antigen ROR1 is expressed by a variety of human cancers","volume":"181","author":"Zhang","year":"2012","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.blre.2025.101273_bb0470","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.4049\/jimmunol.1801327","article-title":"Cutting edge: ROR1\/CD19 receptor complex promotes growth of mantle cell lymphoma cells independently of the B cell receptor-BTK signaling pathway","volume":"203","author":"Zhang","year":"2019","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.blre.2025.101273_bb0475","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165694","article-title":"Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma","volume":"133","author":"Jiang","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101273_bb0480","article-title":"USP14: structure, function, and target inhibition","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.blre.2025.101273_bb0485","doi-asserted-by":"crossref","first-page":"616","DOI":"10.7150\/ijms.80467","article-title":"USP14 promotes the malignant progression and ibrutinib resistance of mantle cell lymphoma by stabilizing XPO1","volume":"20","author":"Zhang","year":"2023","journal-title":"Int J Med Sci"},{"issue":"6","key":"10.1016\/j.blre.2025.101273_bb0490","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1158\/1541-7786.MCR-18-0256","article-title":"Metabolic detection of Bruton\u2019s tyrosine kinase inhibition in mantle cell lymphoma cells","volume":"17","author":"Lee","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"6","key":"10.1016\/j.blre.2025.101273_bb0495","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3324\/haematol.2022.281538","article-title":"Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma","volume":"108","author":"Li","year":"2023","journal-title":"Haematologica"},{"issue":"491","key":"10.1016\/j.blre.2025.101273_bb0500","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.blre.2025.101273_bb0505","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.blre.2025.101273_bb0510","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1182\/bloodadvances.2022009389","article-title":"Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.blre.2025.101273_bb0515","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"7332","key":"10.1016\/j.blre.2025.101273_bb0520","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"7718","key":"10.1016\/j.blre.2025.101273_bb0525","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","article-title":"A multiprotein supercomplex controlling oncogenic signalling in lymphoma","volume":"560","author":"Phelan","year":"2018","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.blre.2025.101273_bb0530","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1073\/pnas.1921187117","article-title":"Regulation of B cell receptor-dependent NF-kappaB signaling by the tumor suppressor KLHL14","volume":"117","author":"Choi","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"34","key":"10.1016\/j.blre.2025.101273_bb0535","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1038\/onc.2017.96","article-title":"PIM1 induces cellular senescence through phosphorylation of UHRF1 at Ser311","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.blre.2025.101273_bb0540","first-page":"2489","article-title":"The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma","volume":"6","author":"Kuo","year":"2016","journal-title":"Am J Cancer Res"},{"issue":"7","key":"10.1016\/j.blre.2025.101273_bb0545","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-16-0555","article-title":"Combination of ibrutinib and ABT-199 in diffuse large B-cell lymphoma and follicular lymphoma","volume":"16","author":"Kuo","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"50","key":"10.1016\/j.blre.2025.101273_bb0550","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1038\/sj.onc.1204926","article-title":"Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer","volume":"20","author":"Catz","year":"2001","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.blre.2025.101273_bb0555","first-page":"2209","article-title":"PDGFD induces ibrutinib resistance of diffuse large B-cell lymphoma through activation of EGFR","volume":"21","author":"Jin","year":"2020","journal-title":"Mol Med Rep"},{"issue":"4","key":"10.1016\/j.blre.2025.101273_bb0560","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040632","article-title":"Drug resistance and endoplasmic reticulum stress in hepatocellular carcinoma","volume":"11","author":"Khaled","year":"2022","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.blre.2025.101273_bb0565","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41401-020-00505-3","article-title":"Activation of unfolded protein response overcomes ibrutinib resistance in diffuse large B-cell lymphoma","volume":"42","author":"Zhang","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.blre.2025.101273_bb0570","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ceca.2017.08.004","article-title":"Calcium signaling at the endoplasmic reticulum: fine-tuning stress responses","volume":"70","author":"Carreras-Sureda","year":"2018","journal-title":"Cell Calcium"},{"issue":"9","key":"10.1016\/j.blre.2025.101273_bb0575","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092146","article-title":"Integration of metabolomics and gene expression profiling elucidates IL4I1 as modulator of ibrutinib resistance in ABC-diffuse large B cell lymphoma","volume":"13","author":"Choueiry","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"18","key":"10.1016\/j.blre.2025.101273_bb0580","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1182\/bloodadvances.2020001685","article-title":"Targeting phosphatidylinositol 3 kinase-beta and -delta for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.blre.2025.101273_bb0585","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2025.101273_bb0590","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2025.101273_bb0595","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/blood-2017-10-811752","article-title":"BTK(Cys481Ser) drives ibrutinib resistance via ERK1\/2 and protects BTK(wild-type) MYD88-mutated cells by a paracrine mechanism","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"issue":"589","key":"10.1016\/j.blre.2025.101273_bb0600","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaw4204","article-title":"Short-term cellular memory tunes the signaling responses of the chemokine receptor CXCR4","volume":"12","author":"Spinosa","year":"2019","journal-title":"Sci Signal"},{"issue":"1","key":"10.1016\/j.blre.2025.101273_bb0605","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom\u2019s macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2025.101273_bb0610","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/bjh.16463","article-title":"Genomic evolution of ibrutinib-resistant clones in Waldenstrom macroglobulinaemia","volume":"189","author":"Jimenez","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2025.101273_bb0615","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/sji.12333","article-title":"Targets for ibrutinib beyond B cell malignancies","volume":"82","author":"Berglof","year":"2015","journal-title":"Scand J Immunol"},{"issue":"3","key":"10.1016\/j.blre.2025.101273_bb0620","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1084\/jem.20041817","article-title":"Dok-1 and Dok-2 are negative regulators of lipopolysaccharide-induced signaling","volume":"201","author":"Shinohara","year":"2005","journal-title":"J Exp Med"},{"issue":"10277","key":"10.1016\/j.blre.2025.101273_bb0625","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101273_bb0630","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1182\/blood-2022-163596","article-title":"Efficacy and safety of nemtabrutinib, a wild-type and C481S-mutated Bruton tyrosine kinase inhibitor for B-cell malignancies: updated analysis of the open-label phase 1\/2 dose-expansion bellwave-001 study","volume":"140","author":"Woyach","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2025.101273_bb0635","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2021.280061","article-title":"Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton\u2019s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies","volume":"107","author":"Allan","year":"2022","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.blre.2025.101273_bb0640","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.18632\/oncotarget.24310","article-title":"First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL","volume":"9","author":"Byrd","year":"2018","journal-title":"Oncotarget"},{"issue":"26","key":"10.1016\/j.blre.2025.101273_bb0645","first-page":"3137","article-title":"Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders","volume":"141","author":"Thompson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101273_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106577","article-title":"Recent research of BTK inhibitors: methods of structural design, pharmacological activities, manmade derivatives and structure-activity relationship","volume":"138","author":"Wang","year":"2023","journal-title":"Bioorg Chem"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2025.101273_bb0655","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2019-125488","article-title":"BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2025.101273_bb0660","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.blre.2025.101273_bb0665","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res"},{"issue":"8","key":"10.1016\/j.blre.2025.101273_bb0670","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-019-0440-x","article-title":"Degradation of Bruton\u2019s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas","volume":"33","author":"Sun","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2025.101273_bb0675","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101273_bb0680","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2023-180109","article-title":"First results from a phase 1, first-in-human study of the Bruton\u2019s tyrosine kinase (BTK) degrader Bgb-16673 in patients (pts) with relapsed or refractory (R\/R) B-cell malignancies (BGB-16673-101)","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101273_bb0685","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.blre.2025.101273_bb0690","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2025.101273_bb0695","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1021\/acs.jmedchem.2c00030","article-title":"Medicinal chemistry strategies for the development of Bruton\u2019s tyrosine kinase inhibitors against resistance","volume":"65","author":"Sun","year":"2022","journal-title":"J Med Chem"},{"issue":"14","key":"10.1016\/j.blre.2025.101273_bb0700","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1080\/10428194.2023.2256914","article-title":"Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies","volume":"64","author":"Smith","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.blre.2025.101273_bb0705","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.2943","article-title":"Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management","volume":"40","author":"Eyre","year":"2022","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.blre.2025.101273_bb0710","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.hoc.2021.03.008","article-title":"Treatment of chronic lymphocytic leukemia after discontinuation of Bruton\u2019s tyrosine kinase inhibitors","volume":"35","author":"Thompson","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"10.1016\/j.blre.2025.101273_bb0715","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-22-3934","article-title":"Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax","volume":"30","author":"Jain","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.blre.2025.101273_bb0720","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2025.101273_bb0725","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.blre.2025.101273_bb0730","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1200\/JCO.22.02283","article-title":"Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study","volume":"41","author":"Munir","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.blre.2025.101273_bb0735","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2025.101273_bb0740","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1016\/S2352-3026(22)00211-3","article-title":"Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial","volume":"9","author":"Cramer","year":"2022","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.blre.2025.101273_bb0745","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1182\/blood.2023020013","article-title":"Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)\/TP53mut","volume":"142","author":"Huber","year":"2023","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2025.101273_bb0750","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.blre.2025.101273_bb0755","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood.2024024510","article-title":"Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed\/refractory CLL: the phase 1b BRUIN trial","volume":"144","author":"Roeker","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101273_bb0760","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2022-164772","article-title":"NX-2127-001, a first-in-human trial of NX-2127, a Bruton\u2019s tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies","volume":"140","author":"Mato","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.blre.2025.101273_bb0765","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1056\/NEJMx140036","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"15 Supplement","key":"10.1016\/j.blre.2025.101273_bb0770","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1158\/1538-7445.AM2015-1742","article-title":"Abstract 1742: Ibrutinib plus proteasome or MALT1 inhibitors overcome resistance to BCR antagonists in CARD11 mutant-expressing B-lymphoma cells","volume":"75","author":"Xue","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2025.101273_bb0775","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1182\/blood-2022-170985","article-title":"Novel BTK mutations conferring resistance to the second-generation, irreversible BTK inhibitor orelabrutinib (ICP-022)","volume":"140","author":"Zhu","year":"2022","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T02:36:18Z","timestamp":1745116578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":155,"alternative-id":["S0268960X25000189"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101273","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101273"}}